Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksByotrol Regulatory News (BYOT)

Share Price Information for Byotrol (BYOT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.10
Bid: 0.05
Ask: 0.15
Change: 0.00 (0.00%)
Spread: 0.10 (200.00%)
Open: 0.125
High: 0.00
Low: 0.00
Prev. Close: 0.10
BYOT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Licence and Product Supply Agreement with Tristel

23 Mar 2020 07:00

RNS Number : 1185H
Byotrol PLC
23 March 2020
 

 

 

 

 

Byotrol plc ("Byotrol" or the "Company")

Know-How Licence and Product Supply Agreement with Tristel plc

 

 

Byotrol is pleased to announce a new collaboration ("the Agreement") with fellow infection prevention and control specialists Tristel plc.

 

The Agreement relates to three specific technologies

 

1. A concentrated surface disinfectant initially targeted for use in hospitals, dispensed from Tristel's proprietary Cache system of innovative packaging solutions; and

2. A concentrated surface disinfectant with long-lasting (8 hour) anti-microbial efficacy also to be dispensed from Tristel's proprietary Cache system. This product is a concentrate version of ACTIZONE, a Solvay technology developed in conjunction with Byotrol; and

3. A unique surface disinfectant combining Tristel's proprietary sporicidal chemistry, with Byotrol's long-lasting anti-microbial technology, also based on the ACTIZONE technology platform. The combined product will speedily eliminate spores on application, and will then remain active against microbes for an 8-hour period after application. Tristel will incorporate the jointly developed formulation in several packaging formats under the family name "Tristel8". 

The Agreement has a duration of 10 years and will be exclusive in hospitals in the UK and Ireland and non-exclusive elsewhere. Under the terms of the Agreement, Tristel will pay to Byotrol a combination of product supply payments, royalties and fees, based on success but with meaningful minimum guarantee payments to Byotrol each year.

 

 

David Traynor, Chief Executive of Byotrol, said:

 

"We are really pleased to be working with Tristel in this way and are particularly pleased that our chemistries now work in combination, with genuinely unique new product claims at a key time in infection control. This agreement now brings our products to many more customers in healthcare and beyond, and in formats that we could not do on our own"

 

 

Enquiries:

 

Byotrol plc

David Traynor - Chief Executive Officer

Nic Hellyer - Chief Financial Officer 01925 742 000

 

finnCap

Geoff Nash/ Richard Chambers - Corporate Finance 020 7220 0500

 

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading infection prevention and control technology company, operating globally in the Food, Industrial, Healthcare and Consumer sectors, providing low toxicity products with a broad-based and long-lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, mycobacteria and algae.

 

Powerful, long-lasting and gentle, Byotrol's products can be used stand-alone or as ingredients within existing products, where Byotrol can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Founded in 2005, the Company develops technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to www.byotrol.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRJTMMTMTMTTJM
Date   Source Headline
1st Nov 202111:36 amRNSTotal Voting Rights
1st Nov 202111:20 amRNSHolding(s) in Company
28th Oct 202111:40 amRNSExercise of Options & Total Voting Rights
20th Oct 20214:46 pmRNSResult of AGM
1st Oct 20217:00 amRNSSale of Byotrol24 in the Americas
27th Sep 20214:36 pmRNSPosting of Annual Report & Accounts/Notice of AGM
1st Sep 20217:00 amRNSInvestor Presentation
20th Aug 202110:01 amRNSHolding(s) in Company
19th Aug 20217:00 amRNSFinal Results
27th Jul 20217:00 amRNSNotice of Results
21st Jun 20217:00 amRNSAlcohol-free Hand Sanitisers Backed by TIGGR
28th Apr 20219:47 amRNSExercise of Options & Total Voting Rights
27th Apr 20217:00 amRNSHolding(s) in Company
22nd Apr 20212:05 pmRNSSecond Price Monitoring Extn
22nd Apr 20212:00 pmRNSPrice Monitoring Extension
22nd Apr 20217:00 amRNSTrading Update
16th Apr 20214:40 pmRNSHolding(s) in Company
26th Feb 20217:00 amRNSTest Protocol for Testing Anti-Viral Efficacy
21st Jan 202110:30 amRNSExercise of Options & Total Voting Rights
8th Jan 20219:36 amRNSCapital reduction
21st Dec 20208:26 amRNSHolding(s) in Company
7th Dec 20207:00 amRNSInterim Results
13th Nov 202011:30 amRNSResult of AGM
13th Nov 20207:00 amRNSAGM Statement
6th Nov 202011:27 amRNSAnnual General Meeting – update on arrangements
20th Oct 20201:42 pmRNSPosting of circular & notice of AGM
14th Oct 20204:30 pmRNSExercise of Options & Total Voting Rights
13th Oct 202011:09 amRNSPUBLICATION OF AUDITED RESULTS
25th Sep 20207:00 amRNSDirector Dealing
25th Sep 20207:00 amRNSInvestor Presentation
24th Sep 20207:00 amRNSPreliminary Results
7th Sep 20207:00 amRNSGrant Award
27th Aug 20208:07 amRNSHolding(s) in Company
20th Aug 20208:10 amRNSHolding(s) in Company
18th Aug 20205:01 pmRNSHolding(s) in Company
18th Aug 20204:42 pmRNSSecond Price Monitoring Extn
18th Aug 20204:36 pmRNSPrice Monitoring Extension
17th Aug 20209:05 amRNSSecond Price Monitoring Extn
17th Aug 20209:00 amRNSPrice Monitoring Extension
3rd Aug 20207:00 amRNSTrading Update
16th Jul 20202:40 pmRNSHolding(s) in Company
3rd Jul 20207:00 amRNSExercise of Options and Total Voting Rights
29th Jun 20204:29 pmRNSHolding(s) in Company
19th May 202012:08 pmRNSHolding(s) in Company
14th May 20207:00 amRNSLicense Agreements and Update on Trading
27th Apr 20207:30 amRNSTrading Update
22nd Apr 20204:41 pmRNSSecond Price Monitoring Extn
22nd Apr 20204:36 pmRNSPrice Monitoring Extension
8th Apr 20207:00 amRNSHolding(s) in Company
6th Apr 202011:26 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.